Earnings ·
Immuron reports $7.7M FY2026 revenue, net loss of $(3.8)M as it pursues strategic reset to cut cash burn
IMRNImmuron Ltd
Immuron Limited filed a Form 6-K to report on its CEO Steven Lydeamore's presentation at the Coffee Microcaps Conference held in Sydney on September 22, 2026. The filing discloses FY2026 financial results showing global sales revenue of $7.7 million, up 6% year-over-year, with a net loss of $(3.8) million and cash reserves of A$9.0 million as of June 30, 2026. Key operational highlights include the completion of an n=851 Travelan trial, FDA approval for an IMM-529 IND application, and the execution of an exclusive U.S. distribution agreement in September 2026. The company announced a strategic reset to partner its clinical assets, IMM-124E and IMM-529, aiming to reduce cash burn and improve profitability through licensing deals while maintaining commercial operations for Travelan and ProIBS. Immuron Limited is an Australian biopharmaceutical company focused on developing and commercializing orally delivered targeted polyclonal antibodies for the treatment of infectious diseases.